Jump to content

Homotaurine: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
link
→See also: already linked and described in the text
Line 57: Line 57:


One study in rats showed that homotaurine suppressed ethanol-stimulated dopamine release, as well as ethanol intake and preference in rats in a way similar to the ''N''-acetyl [[derivative (chemistry)|derivative]] of homotaurine, [[acamprosate]].<ref>{{cite journal | doi = 10.1016/s0014-2999(02)01272-4| title = Effects of acute acamprosate and homotaurine on ethanol intake and ethanol-stimulated mesolimbic dopamine release| journal = European Journal of Pharmacology| volume = 437| pages = 55–61| year = 2002| last1 = Olive| first1 = M.Foster| last2 = Nannini| first2 = Michelle A.| last3 = Ou| first3 = Christine J.| last4 = Koenig| first4 = Heather N.| last5 = Hodge| first5 = Clyde W.}}</ref> Acamprosate was approved by the FDA in 2004 to treat alcohol dependence.<ref name=OrgChem2007>{{cite book | last1 = Lednicer | first1 = Daniel | name-list-format = vanc | title = The Organic Chemistry of Drug Synthesis | date = 2008 | publisher = John Wiley & Sons | location = Hoboken | isbn = 978-0-470-18066-2 | edition = 7th | url = https://books.google.com/books?id=N6OAhuiHqiIC&pg=PA15 | page = 15 }}</ref>
One study in rats showed that homotaurine suppressed ethanol-stimulated dopamine release, as well as ethanol intake and preference in rats in a way similar to the ''N''-acetyl [[derivative (chemistry)|derivative]] of homotaurine, [[acamprosate]].<ref>{{cite journal | doi = 10.1016/s0014-2999(02)01272-4| title = Effects of acute acamprosate and homotaurine on ethanol intake and ethanol-stimulated mesolimbic dopamine release| journal = European Journal of Pharmacology| volume = 437| pages = 55–61| year = 2002| last1 = Olive| first1 = M.Foster| last2 = Nannini| first2 = Michelle A.| last3 = Ou| first3 = Christine J.| last4 = Koenig| first4 = Heather N.| last5 = Hodge| first5 = Clyde W.}}</ref> Acamprosate was approved by the FDA in 2004 to treat alcohol dependence.<ref name=OrgChem2007>{{cite book | last1 = Lednicer | first1 = Daniel | name-list-format = vanc | title = The Organic Chemistry of Drug Synthesis | date = 2008 | publisher = John Wiley & Sons | location = Hoboken | isbn = 978-0-470-18066-2 | edition = 7th | url = https://books.google.com/books?id=N6OAhuiHqiIC&pg=PA15 | page = 15 }}</ref>

==See also==
*[[Acamprosate]] – a derivative of homotaurine


== References ==
== References ==

Revision as of 14:27, 20 September 2018

Homotaurine[1]
Skeletal formula
Ball-and-stick model
Names
IUPAC name
3-Aminopropane-1-sulfonic acid
Other names
Tramiprosate; Alzhemed; 3-APS
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
ECHA InfoCard 100.020.889 Edit this at Wikidata
KEGG
  • InChI=1S/C3H9NO3S/c4-2-1-3-8(5,6)7/h1-4H2,(H,5,6,7) checkY
    Key: SNKZJIOFVMKAOJ-UHFFFAOYSA-N checkY
  • InChI=1/C3H9NO3S/c4-2-1-3-8(5,6)7/h1-4H2,(H,5,6,7)
    Key: SNKZJIOFVMKAOJ-UHFFFAOYAT
  • O=S(=O)(O)CCCN
Properties
C3H9NO3S
Molar mass 139.17 g·mol−1
Melting point 293 °C (559 °F; 566 K) (decomposition)
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
checkY verify (what is checkY☒N ?)

Homotaurine (also known as tramiprosate (INN), 3-amino-1-propanesulfonic acid, or 3-APS) is a synthetic organic compound. It is analogous to taurine, but with an extra carbon in its chain. It has GABAergic activity, apparently by mimicking GABA, which it resembles.[2]

Homotaurine was investigated in a Phase III clinical trial as a potential treatment for Alzheimer's disease that did not show efficacy in its primary endpoints.[3]

Biochemical properties

In preclinical studies it had been found to bind to soluble amyloid beta and inhibit the formation of neurotoxic aggregates.[3][4] Homotaurine has also shown anticonvulsant activities, reduction in skeletal muscle tonus, and hypothermic activity.[5]

Homotaurine has been reported as a GABA antagonist,[2] as well as a GABA agonist.[5][6] In vitro studies have found that homotaurine is a GABAA partial agonist[7] as well as a GABAB receptor partial agonist with low efficacy, becoming an antagonist and a displacing full agonist of GABA or baclofen at this receptor.[8] In a study in rats, homotaurine reversed the catatonia induced by baclofen (the prototypical GABAB agonist),[9] and was able to produce analgesia via the GABAB receptor, an effect that was abolished when CGP-35348, a GABAB receptor antagonist was applied.[10][11]

One study in rats showed that homotaurine suppressed ethanol-stimulated dopamine release, as well as ethanol intake and preference in rats in a way similar to the N-acetyl derivative of homotaurine, acamprosate.[12] Acamprosate was approved by the FDA in 2004 to treat alcohol dependence.[2]

References

  1. ^ "Homotaurine". Sigma-Aldrich.
  2. ^ a b c Lednicer, Daniel (2008). The Organic Chemistry of Drug Synthesis (7th ed.). Hoboken: John Wiley & Sons. p. 15. ISBN 978-0-470-18066-2. {{cite book}}: Unknown parameter |name-list-format= ignored (|name-list-style= suggested) (help)
  3. ^ a b Caltagirone, C.; Ferrannini, L.; Marchionni, N.; Nappi, G.; Scapagnini, G.; Trabucchi, M. (2012). "The potential protective effect of tramiprosate (homotaurine) against Alzheimer's disease: A review". Aging Clinical and Experimental Research. 24 (6): 580–7. doi:10.3275/8585. PMID 22961121.
  4. ^ Aisen, Paul; Gauthier, Serge; Vellas, Bruno; Briand, Richard; Saumier, Daniel; Laurin, Julie; Garceau, Denis (2007). "Alzhemed: A Potential Treatment for Alzheimers Disease". Current Alzheimer Research. 4 (4): 473–478. doi:10.2174/156720507781788882.
  5. ^ a b Oja SS and Kontro P. (2013). Lajtha ANS (ed.). Chapter 18: Taurine. Springer Science & Business Media. p. 520. ISBN 9781468443677. {{cite book}}: |work= ignored (help)
  6. ^ Armen H. Tashjian and Ehrin J. Armstrong. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. Edited by David E. Golan. Lippincott Williams & Wilkins, 2011 ISBN 9781451118056. Page 308
  7. ^ Reyes-Haro, Daniel; Cabrera-Ruíz, Elizabeth; Estrada-Mondragón, Argel; Miledi, Ricardo; Martínez-Torres, Ataúlfo (2014). "Modulation of GABA-A receptors of astrocytes and STC-1 cells by taurine structural analogs". Amino Acids. 46 (11): 2587–2593. doi:10.1007/s00726-014-1813-0. PMID 25119985.
  8. ^ Giotti, A.; Luzzi, S.; Spagnesi, S.; Zilletti, Lucilla (1983). "Homotaurine: A GABAB antagonist in guinea-pig ileum". British Journal of Pharmacology. 79 (4): 855–862. doi:10.1111/j.1476-5381.1983.tb10529.x.
  9. ^ Mehta, A.; Ticku, M. (1987). "Baclofen induces catatonia in rats". Neuropharmacology. 26 (9): 1419–1423. doi:10.1016/0028-3908(87)90108-0.
  10. ^ Serrano, M.Isabel; Serrano, Jose S.; Fernández, Ana; Asadi, Ihklas; Serrano-Martino, M.Carmen (1998). "GABAB Receptors and Opioid Mechanisms Involved in Homotaurine-Induced Analgesia". General Pharmacology: The Vascular System. 30 (3): 411–415. doi:10.1016/s0306-3623(97)00279-6.
  11. ^ Serrano, Maria Isabel; Serrano, Jose S.; Asadi, Ikhlas; Fernandez, Ana; Serrano-Martino, Maria Carmen (2001). "Role of K+-channels in homotaurine-induced analgesia". Fundamental and Clinical Pharmacology. 15 (3): 167–173. doi:10.1046/j.1472-8206.2001.00026.x.
  12. ^ Olive, M.Foster; Nannini, Michelle A.; Ou, Christine J.; Koenig, Heather N.; Hodge, Clyde W. (2002). "Effects of acute acamprosate and homotaurine on ethanol intake and ethanol-stimulated mesolimbic dopamine release". European Journal of Pharmacology. 437: 55–61. doi:10.1016/s0014-2999(02)01272-4.
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Homotaurine&oldid=860413567"